Capecitabine in the Perioperative Treatment of Rectal Cancer (Rektum-III)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01500993 |
Recruitment Status :
Completed
First Posted : December 29, 2011
Last Update Posted : November 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rectal Cancer | Drug: Capecitabine Drug: 5-FU | Phase 3 |
5-Fluorouracil (5-FU) based chemoradiotherapy (CRT) is regarded a standard perioperative treatment in locally advanced rectal cancer (LARC). We investigate the replacement of 5-FU by the oral pro-drug capecitabine (cape) within a randomized phase III trial. Patients aged ≥18 years with LARC stage II or III are recruited into this two-arm, two-cohort randomized non-inferiority phase-III trial (arm A: cape, arm B: 5-FU; cohort [C] I: adjuvant, C II: neoadjuvant). Regimens: Arm A: CRT: 50.4 Gy + cape 1,650 mg/m² days 1-38 plus five cycles of cape 2,500 mg/m² d 1-14, repeated d 22 (C I: 2 x cape, CRT, 3 x cape; C II: CRT, TME surgery followed by cape x 5). Arm B: CRT: 50.4 Gy + infusional 5-FU 225 mg/m² daily [C I] or infusional 5-FU 1,000 mg/m² d 1-5 and 29-33 [C II] plus 4 cycles of bolus 5-FU 500mg/m² d 1-5, repeated d 29 (C I: 2 x 5-FU, CRT, 2 x 5-FU; C II: CRT, TME surgery followed by 5-FU x 4). Primary endpoint is 5-year overall survival (OS), secondary endpoints comprise 3-year disease-free survival (DFS) and safety.
The study is designed to investigate whether 5- year overall survival rate (SR5) is non-inferior in arm A versus arm B. We hypothesize that SR5 in the standard arm B is 57.5%. Sample size calculation is performed with a power of 80% and a type I error of 5% and with a drop-out rate of 5%. Therefore, a total of at least 372 evaluable patients (i.e. 186 per arm) is required to confirm non-inferiority of the experimental arm A with a non-inferiority margin of maximal 12.5% and a median follow-up time of 48 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 401 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | 5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial |
Study Start Date : | March 2002 |
Actual Primary Completion Date : | March 2011 |
Actual Study Completion Date : | March 2011 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 5-Fluorouracil (5-FU)
Drug - 5FU based chemoradiotherapy and chemotherapy
|
Drug: 5-FU
4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
Other Name: 5-Fluorouracil |
Experimental: Capecitabine
Drug - Capecitabine-based radiochemotherapy and chemotherapy
|
Drug: Capecitabine
Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
Other Name: Xeloda |
- Overall survival [ Time Frame: 5-year ]
- disease-free survival (DFS) [ Time Frame: 3-year DFS ]
- Local recurrence rate [ Time Frame: 5 years ]Percentage of patient with local recurrence
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible patients are 18 years or older and have histologically confirmed adenocarcinoma of the rectum (defined as the distal border of the tumour less than 16 cm from the anal verge measured by rigid rectoscopy) with no evidence of distant metastases (identified by abdominal ultrasound or CT scan and chest radiography).
- Patients in the adjuvant cohort have undergone R0-resection by total mesorectal excision (TME) of a pT3-4 N any or T any N positive non-metastatic rectal cancer.
- Patients treated in the neoadjuvant cohort need to have a clinical T3-4 N any or T any N positive tumour staged by endoscopic ultrasound, provided the lower border of the tumour is located 0 - 16 cm from the anal verge measured by rigid rectoscopy and the primary tumour is deemed resectable by TME surgery on the basis of clinical assessment. Other eligibility criteria comprise: WHO status of zero or one; adequate liver, renal, and bone marrow function defined as follows: leucocyte count > 3,500/µl, thrombocyte count > 100,000/µl, hemoglobin > 10.0 g/dl; serum bilirubin < 2.0 mg/dl, serum creatinine < 2.0 mg/dl.
Exclusion criteria:
- Prior treatment for rectal cancer, prior chemo- or immunotherapy, prior pelvic radiotherapy, or a history of other malignant diseases within the past five years with the exception of successfully treated basal carcinoma of the skin or carcinoma in situ of the uterine cervix.
- Participation in another trial, pregnancy, breast-feeding, unwillingness to use effective contraception, or a medical condition or concomitant illness which could potentially interfere with compliance to the protocol are regarded as exclusion criteria, as well.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01500993
Germany | |
Dr Martina Grunewald | |
Aschersleben, Germany | |
Dr Hans Walter Lindemann | |
Hagen, Germany | |
Prof Hartmut Link | |
Kaiserslautern, Germany | |
Dr Elisabeth Fritz | |
Koblenz, Germany | |
Dr Stephan Kremers | |
Lebach, Germany | |
Dr Lothar Müller | |
Leer, Germany | |
Dr Christain Constantin | |
Lemgo, Germany | |
Dr Erika Kettner | |
Magdeburg, Germany | |
Dr Markus Moehler | |
Mainz, Germany | |
Dr Udo Hieber | |
Mannheim, Germany | |
Prof Ralf Hofheinz | |
Mannheim, Germany | |
Dr Matthias Hipp | |
Regensburg, Germany | |
Prof Axel Matzdorff | |
Saarbrücken, Germany | |
Dr Stephan Laechelt | |
Tübingen, Germany |
Study Chair: | Ralf Hofheinz, MD | Universitätsmedizin Mannheim Germany, University of Heidelberg | |
Study Chair: | Frederik Wenz, MD | Universitätsmedizin Mannheim, Germany, University of Heidelberg | |
Study Chair: | Stefan Post, MD | Universitätsmedizin Mannheim, Germany, University of Heidelberg | |
Study Chair: | Andreas Hochhaus, MD | Universitätsklinikum Jena, Germany |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Frederik Wenz, Co-Investigator, Head Department of Radiation Oncology Mannheim, Universitätsmedizin Mannheim |
ClinicalTrials.gov Identifier: | NCT01500993 |
Other Study ID Numbers: |
Rektum III |
First Posted: | December 29, 2011 Key Record Dates |
Last Update Posted: | November 27, 2020 |
Last Verified: | November 2020 |
Rectal cancer Chemoradiotherapy Capecitabine phase-III trial |
Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases |
Rectal Diseases Capecitabine Fluorouracil Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |